Informações de Schrodinger Inc

Mais detalhes de Schrodinger Inc Empresa

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.



Código da empresaSDGR

Nome da EmpresaSchrodinger Inc

Data de listagemFeb 06, 2020

CEODr. Ramy Farid, Ph.D.

Número de funcionários891

Tipo de títulosOrdinary Share

Fim do ano fiscalFeb 06

Endereço1540 Broadway

CidadeNEW YORK

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal10036

Telefone15032991150

Sitehttps://www.schrodinger.com

Código da empresaSDGR

Data de listagemFeb 06, 2020

CEODr. Ramy Farid, Ph.D.

Executivos da empresa Schrodinger Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.37%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

Michael M. Lynton ,

Independent Chairman of the Board

12.25K

+95.95%

Ms. Bridget Anne Van Kralingen

Independent Director

11.50K

+14.99%

Mr. Mannix Aklian

Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing

--

Mr. Gary Ginsberg, J.D.

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.37%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

On-premise software

15.74M

28.75%

Drug discovery services

13.94M

25.46%

Hosted software

11.13M

20.32%

Software maintenance

6.78M

12.38%

Contribution

4.51M

8.24%

Outro

2.66M

4.85%

Por RegiãoUSD

Nome

Receita

Proporção

United States

34.05M

62.18%

EMEA

13.56M

24.77%

APAC

6.97M

12.73%

Rest of World

175.00K

0.32%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

On-premise software

15.74M

28.75%

Drug discovery services

13.94M

25.46%

Hosted software

11.13M

20.32%

Software maintenance

6.78M

12.38%

Contribution

4.51M

8.24%

Outro

2.66M

4.85%

Distribuição de ações

Atualizado em: sáb, 1 de nov

Investidores

Tipos de investidores

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

12.66%

Bill & Melinda Gates Foundation Trust

10.82%

The Vanguard Group, Inc.

9.81%

Rubric Capital Management LP

7.75%

Amova Asset Management Co., Ltd.

7.06%

Outro

51.89%

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

12.66%

Bill & Melinda Gates Foundation Trust

10.82%

The Vanguard Group, Inc.

9.81%

Rubric Capital Management LP

7.75%

Amova Asset Management Co., Ltd.

7.06%

Outro

51.89%

Tipos de investidores

Investidores

Proporção

Investment Advisor

46.69%

Investment Advisor/Hedge Fund

29.18%

Hedge Fund

19.49%

Endowment Fund

10.82%

Individual Investor

2.64%

Research Firm

2.60%

Bank and Trust

1.72%

Pension Fund

0.91%

Venture Capital

0.13%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

545

71.77M

111.28%

-2.08M

2025Q2

572

66.46M

103.14%

-5.60M

2025Q1

593

67.21M

104.69%

-5.43M

2024Q4

576

64.44M

100.89%

-9.04M

2024Q3

581

67.44M

105.91%

-6.15M

2024Q2

573

64.76M

101.80%

-8.12M

2024Q1

574

63.48M

100.05%

-5.40M

2023Q4

584

62.06M

98.56%

-7.64M

2023Q3

586

63.62M

101.35%

-15.42M

2023Q2

584

64.04M

102.20%

-7.30M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

BlackRock Institutional Trust Company, N.A.

8.17M

12.68%

+419.13K

+5.41%

Jun 30, 2025

Bill & Melinda Gates Foundation Trust

6.98M

10.83%

--

Jun 30, 2025

The Vanguard Group, Inc.

6.60M

10.25%

+74.93K

+1.15%

Jun 30, 2025

Rubric Capital Management LP

5.00M

7.76%

+200.00K

+4.17%

Jun 30, 2025

Amova Asset Management Co., Ltd.

3.65M

5.66%

+187.53K

+5.42%

Jun 30, 2025

Cadian Capital Management LP

3.05M

4.73%

+1.94M

+175.65%

Jun 30, 2025

Stephens Investment Management Group, LLC

2.26M

3.51%

+291.39K

+14.79%

Jun 30, 2025

State Street Investment Management (US)

2.19M

3.39%

-26.19K

-1.18%

Jun 30, 2025

MFS Investment Management

1.49M

2.32%

-598.55K

-28.60%

Jun 30, 2025

ARK Investment Management LLC

1.96M

3.04%

-335.26K

-14.61%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

ARK Genomic Revolution ETF

3.29%

TrueShares Technology, AI & Deep Learning ETF

1.87%

Global X HealthTech ETF

1.47%

SPDR FactSet Innovative Technology ETF

0.99%

Franklin Exponential Data ETF

0.82%

WisdomTree BioRevolution Fund

0.75%

Invesco S&P SmallCap Health Care ETF

0.71%

Franklin Genomic Advancements ETF

0.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.45%

First Trust Multi-Manager Small Cap Opportunities ETF

0.43%

Ver Mais

ARK Genomic Revolution ETF

Proporção3.29%

TrueShares Technology, AI & Deep Learning ETF

Proporção1.87%

Global X HealthTech ETF

Proporção1.47%

SPDR FactSet Innovative Technology ETF

Proporção0.99%

Franklin Exponential Data ETF

Proporção0.82%

WisdomTree BioRevolution Fund

Proporção0.75%

Invesco S&P SmallCap Health Care ETF

Proporção0.71%

Franklin Genomic Advancements ETF

Proporção0.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proporção0.45%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporção0.43%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados